The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1556
Hydrogen Peroxide 40% (Eskata) for Seborrheic Keratoses
The full article is available to subscribers Subscriber Login   

The FDA has approved hydrogen peroxide 40% topical solution (Eskata – Aclaris Therapeutics) for treatment of raised seborrheic keratoses (SKs) in adults. It is the first drug to be approved for this indication. (Hydrogen peroxide is available over the counter for topical use as a 3% solution.)

STANDARD TREATMENT — SKs are benign, usually pigmented skin growths with a wart-like appearance that occur in about 83 million people in the US, primarily middle-aged and older adults.1 They generally do not require treatment, but patients may want them removed for cosmetic reasons or because they have become irritated.2 Cryotherapy with liquid nitrogen is the most common method for removing SKs. It can cause mild pain, scarring, and hyper- or hypopigmentation (pigmentary changes are more common in patients with dark skin). Curettage, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Hydrogen Peroxide 40% (Eskata) for Seborrheic Keratoses
Article code: 1556b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian